Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine

What is it about?

There is no licensed vaccine against the most widely distributed human malaria parasite, Plasmodium vivax. The preerythrocytic stage is a highly attractive target for vaccination, but there is a need to assess novel vaccine candidates, platforms, and adjuvants to improve efficacy. We show an efficacy evaluation of PvCelTOS using clinically relevant vaccine platforms and a challenge with a transgenic parasite

Featured Image

Why is it important?

There is a great need to assess new vaccine candidates, adjuvants and vaccine platforms to develop an efficacious P. vivax malaria vaccine. Efficacy against infection is a major test to identify promising vaccine candidates to be taken forward to clinical trials.

Perspectives